---
document_datetime: 2026-01-05 17:49:02
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/levetiracetam-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: levetiracetam-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1660035
conversion_datetime: 2026-01-06 07:16:24.922348
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Levetiracetam SUN

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IA_IN / | C.I.3 Change(s) in the Summary of Product | 22/12/2025                          |                                             | SmPC and PL                      | To update Section 4.6 of the SmPC and Section 2 of |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317912                     | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |             | the PL to implement the wording agreed by the PRAC following the outcome of the PSUR procedure EMA/PSUR/0000257824 with more recent information on the risk of neurodevelopmental disorders in children exposed prenatally to levetiracetam.                                                                                  |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000265264 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC to include additional information on signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), based on a safety review, following assessment of the same change for the reference product Keppra (EMEA/H/C/WS2722). Section 4 of the PL is updated accordingly. In addition, the MAH made linguistic corrections to the SmPC in Polish language, to align with approved changes in the reference product. | 02/05/2025 | SmPC and PL | To update section 4.8 of the SmPC to include additional information on signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), based on a safety review, following assessment of the same change for the reference product Keppra (EMEA/H/C/WS2722). Section 4 of the PL is updated accordingly |

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000239226         | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised details of local representatives, and to delete United Kingdom (Northern Ireland) from the list of local representatives to comply with the Windsor Framework for labelling and packaging of medicines (QRD template 10.4). Additionally, the MAH took the opportunity to include minor editorial and formatting changes in some of the translations to align with the EN PI and QRD template 10.4.   | 18/12/2024   |     | PL   |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|------|
| Variation type IA_IN / EMA/VR/0000231943 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                                                                                | 22/10/2024   | N/A |      |
| Variation type IA / EMA/VR/0000228680    | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                          | 19/09/2024   | N/A |      |

<div style=\"page-break-after: always\"></div>

| A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Refused   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|